Why the study?
Heterozygous gain-of-function variants in KCNQ2 and KCNQ3 cause neurodevelopmental disorders lacking established treatments, and amitriptyline blocks Kv7.2/Kv7.3 with prior reported efficacy in a single patient.
Does amitriptyline improve clinical and neurodevelopmental domains (such as alertness, communication, behavior, and seizure frequency) in individuals with pathogenic KCNQ2/3 gain-of-function variants?
Does amitriptyline improve clinical and neurodevelopmental domains (such as alertness, communication, behavior, and seizure frequency) in individuals with pathogenic KCNQ2/3 gain-of-function variants?
Although 72% of evaluated individuals with KCNQ2/3 gain-of-function neurodevelopmental disorders showed improvements in at least two clinical domains during amitriptyline treatment, continued improvements after discontinuation in four patients leave the true therapeutic effect unclear and underscore the need for formal n-of-1 trials.
Answers are grounded in this paper and cite their sources.
Amitriptyline was associated with domain improvements in 72% of cases; leaves open efficacy confirmation via prospective n-of-1 trials.
OBJECTIVE: Heterozygous gain-of-function (GOF) variants in KCNQ2 and KCNQ3, encoding the voltage-gated potassium channel subunits Kv7.2 and Kv7.3, lead to neurodevelopmental disorders for which no established treatments are available. Amitriptyline, an antidepressant, blocks Kv7.2/Kv7.3 and has previously been reported to be effective in a single individual with a KCNQ2 GOF variant. We designed a retrospective, single-arm, multicenter study to investigate the effects of amitriptyline in a real-world setting. METHODS: We used a 7-point Likert scale to measure seizure frequency, clinical examination, motor function, alertness, skill acquisition, communication, mood, behavior, self-care, sleep, tiredness, and electroencephalogram at baseline, after a minimum of 6 weeks of intervention, and, if applicable, after discontinuation. Adverse events were assessed in all participants, and the effectiveness of the treatment was evaluated in 11 individuals who received a minimum dosage of .5 mg/kg/day for at least 6 weeks. Data were collected from October 2023 to August 2024. RESULTS: Thirteen individuals, eight with a pathogenic KCNQ2 GOF variant and five with a pathogenic KCNQ3 GOF variant, were included. Nine were female, and the median age at start of amitriptyline was 7.1 years (range = 1.5-20 years). Eleven individuals received a minimum dosage of .5 mg/kg/day for at least 6 weeks. The median dosage of amitriptyline administered was 1 mg/kg/day, with a median treatment duration of 29 weeks. Although amitriptyline was ineffective in two individuals (18%), eight (72%) demonstrated at least minimal improvement in two or more domains, with improvements in alertness and communication being the most frequently reported. In those with reported improvements, amitriptyline was discontinued in four individuals, but continued improvements were seen, to the same or greater extent compared to treatment. The remaining five individuals are on continued treatment because of perceived benefits. SIGNIFICANCE: Overall, the effect of amitriptyline remains unclear, and formal n-of-1 trials are needed to investigate the precise effects of amitriptyline in KCNQ GOF-related neurodevelopmental disorders.
No takes yet. Share an insight, caveat, or question.
Wachter et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: